Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) has been given an average rating of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $79.75.
A number of research analysts have commented on the stock. Craig Hallum reaffirmed a “buy” rating and issued a $78.00 target price on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. B. Riley Financial lifted their price objective on shares of Eton Pharmaceuticals from $70.00 to $81.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Zacks Research downgraded Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 10th. Canaccord Genuity Group lifted their target price on Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Finally, HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, November 6th.
Get Our Latest Research Report on ETON
Eton Pharmaceuticals Stock Down 2.6%
Shares of NASDAQ:ETON opened at $61.99 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.79 and a debt-to-equity ratio of 0.13. Eton Pharmaceuticals has a 52-week low of $14.27 and a 52-week high of $70.64. The business has a fifty day moving average of $55.52 and a two-hundred day moving average of $38.43. The stock has a market cap of $1.79 billion, a P/E ratio of 41.05 and a beta of 0.89.
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. The company had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 104.82%. On average, research analysts expect that Eton Pharmaceuticals will post 1.54 earnings per share for the current year.
Insider Activity
In other news, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares in the company, valued at $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Krempa sold 4,166 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total value of $229,421.62. Following the transaction, the insider owned 43,381 shares in the company, valued at $2,388,991.67. The trade was a 8.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 82,666 shares of company stock valued at $5,045,607 over the last quarter. Corporate insiders own 16.49% of the company’s stock.
Hedge Funds Weigh In On Eton Pharmaceuticals
Several hedge funds have recently bought and sold shares of the company. Hilton Head Capital Partners LLC acquired a new position in Eton Pharmaceuticals during the third quarter worth about $26,000. Global Retirement Partners LLC acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth $26,000. Morse Asset Management Inc acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $35,000. Toth Financial Advisory Corp acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at $43,000. Finally, Sterling Capital Management LLC boosted its position in shares of Eton Pharmaceuticals by 845.7% in the third quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after buying an additional 795 shares during the period. 27.86% of the stock is owned by hedge funds and other institutional investors.
About Eton Pharmaceuticals
Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.
Featured Articles
- Five stocks we like better than Eton Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
